Brief: Quantum Genomics' Scientific Advisory Board recommends next multicentric clinical trials

Quantum Genomics SA

25/11/2015 15:52

Nov 25 (Reuters) - Quantum Genomics SA  ALQGC.PA : 
    * Company's scientific advisory board recommends next 
multicentric clinical trials in Europe and United States 
    * Scientific Advisory Board discussed broadening the scope 
of the next clinical trials in Europe and the United States to 
adopt a multicentric approach, for both high blood pressure 
(QGC001 program) and heart failure (QGC101 program) 
    * Says to speed its development of heart failure treatments, 
it has set itself the goal of launching a Phase IIa clinical 
trial in humans by mid-2016 
 
Source text: http://bit.ly/1SkhNvx 
Further company coverage:  ALQGC.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 6983920;))